NLS Pharmaceutics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

NLS Pharmaceutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-21.2%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-21.2%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

NLS Pharmaceutics gets delisting determination letter from Nasdaq

Oct 05

NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate

Sep 27

NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders

Jul 28

Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation

Mar 04

Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky

Nov 12

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di NLSP siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di NLSP siano aumentati.

Rendimento dei dividendi rispetto al mercato

NLS Pharmaceutics Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di NLSP rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (NLSP)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.2%
Media del settore (Pharmaceuticals)	2.4%
Analista previsionale (NLSP) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di NLSP rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di NLSP rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di NLSP per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché NLSP non ha segnalato alcun pagamento.

NLS Pharmaceutics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

NLS Pharmaceutics Ltd. Highlights Innovative Preclinical Program for First-In-Class Non-Sulfonamide Dual Orexin Receptor Agonists (Doxa) in Narcolepsy and Neurological Disorders

NLS Pharmaceutics AG Announces Resignation of Claudio Bassetti as Member of the Board

NLS Pharmaceutics Regains Full Compliance with Nasdaq Listing Requirements

NLS Pharmaceutics Expects it Regains Compliance with Nasdaq Minimum Bid Price and Stockholders' Equity Requirements

NLS Pharmaceutics AG Announces Termination of Elena Thyen as Chief Financial Officer, Effective October 31, 2024

Kadimastem Ltd (TASE:KDST) signed a letter of intent to acquire NLS Pharmaceutics AG (NasdaqCM:NLSP) in a reverse merger transaction.

NLS Pharmaceutics Ltd. Announces Promising Preclinical Results for Parkinson's Disease Treatments

NLS Pharmaceutics AG, Annual General Meeting, Jun 27, 2024

NLS Pharmaceutics AG Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (Doxa)

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

NLS Pharmaceutics Ltd. announced delayed 20-F filing

NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding

NLS Pharmaceutics Ltd. has filed a Follow-on Equity Offering in the amount of $1.75 million.

NLS Pharmaceutics Ltd. has filed a Follow-on Equity Offering in the amount of $1.75 million.

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

NLS Pharmaceutics Ltd. Approves Board Appointments

NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol

NLS Pharmaceutics AG, Annual General Meeting, Jun 30, 2023

New major risk - Shareholder dilution

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

NLS Pharmaceutics Ltd. Announces the Resignation of Chad Hellmann as Chief Financial Officer

NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement

NLS Pharmaceutics Ltd. Announces New in Vitro Study Results Demonstrating the Agonist Effect of Mazindol ER At the Orexin-2 Receptor

NLS Pharmaceutics Ltd Announces an R&D Update Webcast to Review It’S Growing Portfolio of Pre-Clinical Compounds

NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037

NLS Pharmaceutics AG announced that it expects to receive $30 million in funding from BVF Partners L.P.

NLS Pharmaceutics AG Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder

NLS Pharmaceutics Ltd. Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe

NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice

NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq

NLS Pharmaceutics gets delisting determination letter from Nasdaq

NLS Pharmaceutics Ltd. Announces Positive Top-Line Results from Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate

NLS Pharmaceutics Ltd. Announces Management Changes

Price target decreased to US$8.63

NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders

NLS Pharmaceutics Ltd. Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia

NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification

NLS Pharmaceutics AG Appoints Chad C. Hellmann as Chief Financial Officer

NLS Pharmaceutics AG, Annual General Meeting, May 31, 2022

Price target decreased to US$7.50

NLS Pharmaceutics AG Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER

Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation

NLS Pharmaceutics to Present Interim Top-Line Data for Quilience® (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022

Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky

NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating Narcolepsy

NLS Pharmaceutics AG announced delayed 20-F filing

NLS Pharmaceutics AG Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex

NLS Pharmaceutics AG Announces Change in Company’s Executive Management Team

Independent Director has left the company

NLS Pharmaceutics AG Announces Resignation of Pascal Brenneisen as A Member of the Board of Director

NLS Pharmaceutics Ltd. Approves Board and Committee Appointments

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti